BioAuxilium Research Launches New THUNDER™ TR-FRET Biomarker Assay Kits and an Enhanced Assay Development Service for Drug Discovery
27.2.2023 19:00:00 EET | Business Wire | Press release
At the annual Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in San Diego, BioAuxilium Research Inc., a biotech tool company focused on facilitating access to fully validated assay kits to the biomedical research community, today announced the expansion of its no-wash THUNDER™ time-resolved Förster resonance energy transfer (TR-FRET) technology portfolio by introducing six new biomarker research assay kits, a Reader Control Kit, and an enhanced assay development service for drug discovery research.
BioAuxilium developed the new biomarker assays in response to customer requests for reliable cell-based assays that provide an alternative to expensive immunoassay platforms such as other TR‑FRET and bead-based assay technologies. The new offerings include a panel of six key mouse inflammatory cytokines (CCL-2/MCP1, IFN-beta, IFN-gamma, IL-2, IL-6, and TNF-alpha), expanding the company’s portfolio to a total of 100 cell-based assay kits (76 Cell Signaling Kinases, 23 Biomarkers, and a cAMP Assay). The ready-to-use Reader Control Kit allows users to assess in just 10 minutes the suitability of TR‑FRET compatible microplate readers to perform Europium-based TR-FRET measurements.
The new assay development service offers three types of custom assay solutions: labeling of antibodies with BioAuxilium’s proprietary TR-FRET fluorophores, custom assay development services, and custom kit development services. These comprehensive, yet flexible custom solutions are designed to fast-track assay development, while further reducing risk, turnaround time, and cost.
“BioAuxilium continues to make great strides with the expansion of the THUNDER™ TR-FRET technology portfolio, based on customer demand for high-performing, reliable yet affordable immunoassays,” said Jaime Padros, PhD, President, BioAuxilium Research. “In addition, our decades of experience developing and manufacturing drug discovery assays based on TR-FRET allow us to deliver results within turnaround times and at prices simply unattainable by any other custom assay development service.”
BioAuxilium’s THUNDER™ TR-FRET technology is a robust, proprietary platform based on a FRET pair showing an enhanced spectral compatibility and TR-FRET signal, best antibody pairs selected specifically for TR-FRET, and a panel of optimized lysis and assay buffers. In addition, the “add-incubate-read” protocol of the immunoassay platform, combined with its full compatibility with different TR-FRET readers, facilitates streamlined workflows and automation for high-throughput screening. All THUNDER™ TR-FRET assays are extensively validated to ensure specificity, sensitivity, reproducibility, and lot-to-lot consistency.
About BioAuxilium Research Inc.
BioAuxilium is a private Canadian biotechnology tool company founded by expert assay scientists. It focuses on developing and manufacturing top-quality, highly validated assay kits that accelerate drug discovery and basic research. BioAuxilium’s kits are based on its enhanced proprietary THUNDER™ TR‑FRET technology. They are offered at an outstanding value and are accompanied by information-rich datasheets and expert technical support. BioAuxilium also provides customized services in assay development on a contract basis. Their products and services are available directly to US- and Canada-based customers, and through the company’s network of international distributors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005027/en/
Contact information
Jaime Padros, President
514-312-9033 ext. 101
jaime.padros@bioauxilium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 16:00:00 EEST | Press release
Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading transformative and meaningful customer experiences. These leading organizations are turning everyday interactions into seamless, cross-channel journeys that deliver meaningful business impact and
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 16:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On the demand side, with smart meter integration, Predict+ models each meter individually and performs extensive calculations on actual, historical, and average data to acc
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 15:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 15:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duration while maintaining flexible, up to once-monthly dosing for patients (every three or four weeks for PID). The TAK-881-3001 clinical trial ev
Ouster Releases The REV8 OS Family: The World’s First Native Color Lidar4.5.2026 13:00:00 EEST | Press release
Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leader in sensing and perception for Physical AI, announced today its new family of OS digital lidar sensors, Rev8, powered by its next-generation L4 Ouster Silicon. Ouster Rev8 features the world’s first patented native color lidar sensors, provides up to double the range and resolution of the previous generation, and is designed for functional safety, reliability, affordability, and scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504718668/en/ The REV8 OS Family: The World's First Native Color Lidar. L4 Ouster Silicon: Ouster’s breakthrough L4 architecture doubles the range and resolution of its lidar over the prior generation, adds native-color sensing, and is designed for functional safety. Based on patented Ouster Silicon with embedded Fujifilm color science, the L4 chip results in exquisite color data and hardware-enabled HDR. It boasts 42.9 GMACs of p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom